Limiting perioperative tachycardia (aiming for a heart rate <90 beats per minute throughout the perioperative period) using the ultra-short acting beta-blocker landiolol in patients with cardiovascular risk factors undergoing major surgery might lower the incidence of perioperative myocardial injury. Feasibility of the intervention needs to be proven prior to conduction of a larger trial.

Start Date24 Apr 2026

Sponsor / Collaborator

Insel Gruppe AG

CTR20261124

/ CompletedNot Applicable

一项评价注射用盐酸兰地洛尔在中国健康试验参与者中的药代动力学研究

[Translation] A pharmacokinetic study evaluating landiolol hydrochloride for injection in Chinese healthy trial participants.

主要研究目的：本研究考察空腹条件下使用由中山万汉制药有限公司生产的注射用盐酸兰地洛尔在中国健康试验参与者体内的药动学特征。次要研究目的：观察中山万汉制药有限公司生产的注射用盐酸兰地洛尔在中国健康试验参与者中的安全性。

[Translation]

Primary objective: This study investigated the pharmacokinetic characteristics of landiolol hydrochloride for injection (manufactured by Zhongshan Wanhan Pharmaceutical Co., Ltd.) in healthy participants in a Chinese health trial under fasting conditions. Secondary objective: To observe the safety of landiolol hydrochloride for injection (manufactured by Zhongshan Wanhan Pharmaceutical Co., Ltd.) in healthy participants in a Chinese health trial.

Start Date23 Mar 2026

Sponsor / Collaborator

Zhongshan Wanhan Pharmaceutical Co., Ltd.

[+1]

CTIS2025-523676-23-00

/ Not yet recruitingPhase 4IIT

The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double- blinded, placebo controlled, phase IV pilot trial (STEMILAND-1)

Start Date07 Jan 2026

Sponsor / Collaborator

Medical University of Vienna

100 Clinical Results associated with Landiolol Hydrochloride

100 Translational Medicine associated with Landiolol Hydrochloride

100 Patents (Medical) associated with Landiolol Hydrochloride

488

Literatures (Medical) associated with Landiolol Hydrochloride

01 Jun 2026·CARDIOLOGY IN THE YOUNG

A scoping review of the evidence supporting antiarrhythmic use after paediatric cardiac surgery

Review

Author: Thompson, Elizabeth J. ; Foote, Henry P. ; Hornik, Christoph ; Kohlmann, Taylor ; Zimmerman, Kanecia O. ; Hill, Kevin D. ; Commander, Sarah Jane ; Kilborn, Alison G. ; Sullenger, Rebecca D.

Abstract:

Background::

Arrhythmias after paediatric cardiac surgery occur frequently and contribute to postoperative morbidity and mortality. There is limited literature assessing the safety and efficacy of common antiarrhythmics administered in this population.

Methods::

We systematically searched PubMed and EMBASE for literature on antiarrhythmic use in children <18 years of age after cardiac surgery from 2000 to 2024. Two reviewers independently screened abstracts and then reviewed full-text manuscripts to determine eligibility.

Results::

We identified 28 studies of 3,752 patients across 11 different antiarrhythmics: flecainide, procainamide, esmolol, landiolol, propranolol, amiodarone, sotalol, dexmedetomidine, digoxin, ivabradine, and magnesium. Most studies were small, with 17 enrolling fewer than 100 children. Only eight studies were randomised, 16 were retrospective, 12 were prospective, and one was multicenter. Safety and efficacy endpoints varied widely, limiting our ability to combine data for meta-analysis. Overall, evidence supporting the use of these drugs in children after cardiac surgery was limited.

Conclusion::

Although antiarrhythmics are commonly used in children after cardiac surgery, randomised trials with standardised endpoints to guide choice of therapy are lacking. Pragmatic trials to generate real-world data should be considered to further evaluate the safety and efficacy of various antiarrhythmics in this population.

01 May 2026·EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Pharmacokinetics of Landiolol and Its Metabolite M1 During Renal Replacement Therapy in Septic Shock Patients: A Sub-Study of the Landi-SEP Trial

Article

Author: Klade, Christoph ; Sus, Jan ; Bouvet, Olivier ; Borgstedt, Rainer ; Krumpl, Günther ; Unger, Martin ; Duška, František ; Rehberg, Sebastian ; Krejcy, Kurt ; Černý, Vladimír ; Kirchbaumer-Baroian, Nairi ; Frank, Sandra

BACKGROUND AND OBJECTIVE:

Landiolol, an ultra-short-acting β-blocker, is commonly used to manage tachyarrhythmias, including critically ill patients requiring renal replacement therapy (RRT). Pharmacokinetic (PK) data for landiolol in these patients are lacking. This study aimed to evaluate the PK and dialytic clearance of landiolol and its metabolite, M1, in septic shock patients receiving RRT, with the goal of guiding dosing optimization to ensure safe and effective treatment in this high-risk population.

METHODS:

This pre-defined PK sub-study was embedded within the Landi-SEP trial, which randomized patients with septic shock and persistent tachycardia to receive standard care or standard care with landiolol. Patients from two centers undergoing RRT were included in the sub-study. PK parameters, including dialytic and total clearance and area under the concentration-time curve (AUC), were determined based on plasma concentrations of landiolol and M1. Pharmacodynamic data, including heart rate (HR) and blood pressure (BP), were assessed concurrently.

RESULTS:

Six patients were included in the final analysis. Mean dialytic clearance was 39.3 mL/min for landiolol and 42.3 mL/min for M1. Dialysis accounted for 2.4% of total landiolol clearance and 50.9% of M1 clearance. HR and BP remained stable throughout the sub-study and no adverse events related to hypotension or bradycardia were reported.

CONCLUSION:

Dialysis minimally affected landiolol clearance but removed a substantial proportion of M1. These exploratory data align with current dosing recommendations in patients with renal impairment and suggest that no dose adjustment is required during RRT. Individualized dosing and hemodynamic monitoring remain essential.

TRIAL REGISTRATION:

EU Clinical Trial Register; EudraCT Number: 2017-002138-22.

01 May 2026·Cardiology in review

Landiolol for Treating Arrhythmias: A State-of-The-Art Review

Review

Author: Alagha, Zakaria ; Rasool, Muhammad Haseeul ; Ahmed, Mahmoud Samy ; Aronow, Wilbert S ; Frenkel, Daniel ; Frishman, William H. ; Miller, Daniel ; Ghallab, Muhammad ; Ostrow, Talia H.

This article provides a state-of-the-art review on landiolol, a medication that was recently submitted for 7 approvals. Focusing on its pharmacology, pharmacokinetics, and pharmacodynamics, the analysis underscores landiolol’s unique attributes compared to conventional beta-blockers, particularly esmolol. As a sympatholytic agent, landiolol exhibits a short half-life, high cardioselectivity, and minimal impact on blood pressure, setting it apart in the realm of arrhythmia treatment. The review explores landiolol’s potential applications, emphasizing scenarios where other beta-blockers may be limited. A detailed examination of its efficacy in preventing postoperative atrial fibrillation reveals promising results from clinical trials, suggesting its utility in diverse surgical settings. Additionally, the article delves into landiolol’s role in rate control for atrial fibrillation/flutter, treatment of ventricular tachycardia/fibrillation, and its use in managing sepsis-related tachyarrhythmias. The evolving landscape of landiolol’s applications extends beyond cardiac care, including potential anti-inflammatory, antioxidative, analgesic, and anticancer effects. While the outcomes from various studies are promising, challenges persist, requiring further research to optimize dosing strategies, identify optimal patient populations, and elucidate mechanisms underlying its diverse effects. The potential expansion of landiolol’s applications highlights the importance of ongoing clinical investigation, offering a promising avenue for enhancing arrhythmia management and addressing broader medical needs.

News (Medical) associated with Landiolol Hydrochloride

28 Apr 2026

·www.businesswire.com

AOP Health US Marks First Patient Treated with Rapiblyk® in the United States, Expanding Access to Critical Care Innovation Nationwide

WILMINGTON, Del.--(BUSINESS WIRE)--AOP Health US, LLC today announced that the first patient in the United States has been treated with Rapiblyk® (landiolol) at The Valley Hospital, Paramus, NJ. This marks a key milestone in the company’s U.S. expansion and its efforts to address high unmet medical needs in critical care. AOP Health US is now positioned on a national stage to support clinicians and care teams with an innovative therapeutic option for patients with acute cardiac arrhythmias. Bringing Rapiblyk® into clinical practice in the U.S. enables AOP Health to support critical care teams with a fast-acting treatment option. “This milestone represents an important step forward in improving access to innovative therapies for patients and the clinicians who treat them,” said John Kimmet, General Manager of AOP Health US. “Bringing Rapiblyk® into clinical practice in the U.S. enables us to support critical care teams with a fast-acting treatment option and reflects our commitment to addressing unmet medical needs.” Rapiblyk® (landiolol) is an ultra-short-acting, highly selective beta-1 adrenergic receptor blocker designed for rapid and controlled heart rate management. It is administered intravenously in a monitored hospital setting, particularly in critical care environments. Therapy Approved for All Ages Landiolol received U.S. Food and Drug Administration (FDA) approval in November 2024 and was previously approved for use in Europe, Japan, and Canada. The therapy is approved for all ages and is used to treat abnormal heart rhythms such as atrial fibrillation and atrial flutter. “Cardiac critical care teams require fast, precise tools to stabilize patients with complex and life-threatening conditions,” said Yonathan Litwok, MD, Director of Cardiac Critical Care at The Valley Hospital. “Having access to new treatment options supports our ability to provide high-quality, responsive care to patients in critical situations.” Cardiac critical care is a specialized field focused on patients with severe or unstable cardiovascular conditions requiring continuous monitoring, advanced therapies, and rapid intervention. Effective management in these settings depends on coordinated, team-based care and timely therapeutic options. About Rapiblyk® Rapiblyk® (landiolol) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia (SVT) or irregular rapid heart rate, including atrial fibrillation and atrial flutter, especially in perioperative, postoperative, or critical-care settings. Rapiblyk® provides rapid onset and offset of action, allowing clinicians to achieve precise, controlled rate management with a favorable hemodynamic profile. The product is supplied as an intravenous infusion designed for use in a monitored hospital setting. INDICATION RAPIBLYK® (landiolol) for injection is a beta-adrenergic blocker indicated for the short-term reduction of ventricular rate in: Adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter Pediatric patients with supraventricular tachycardia Important Safety Information Contraindications RAPIBLYK® is contraindicated in patients with: Severe sinus bradycardia Sick sinus syndrome Heart block greater than first degree Decompensated heart failure Cardiogenic shock Pulmonary hypertension Hypersensitivity to landiolol or any of the inactive ingredients Warnings and Precautions Patients with hemodynamic compromise, hypovolemia, or receiving interacting medications are at increased risk of hypotension. Monitor blood pressure closely. Reduce or discontinue RAPIBLYK if hypotension occurs. Bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest, may occur. Monitor heart rate and rhythm. Reduce or discontinue RAPIBLYK for bradyarrhythmia. Beta-blockers may cause depression of myocardial contractility and may precipitate heart failure or cardiogenic shock. At the first sign of impending cardiac failure, discontinue RAPIBLYK and initiate supportive therapy. Beta-blockers may exacerbate bronchospasm. Use caution in patients with reactive airway disease. Discontinue infusion if bronchospasm occurs. Beta-blockers may mask symptoms of hypoglycemia (e.g., tachycardia) and may increase the risk for severe or prolonged hypoglycemia. Monitor blood glucose in patients with diabetes or those at risk. Infusion site reactions including pain, swelling, and erythema have occurred. Avoid infusions into small veins or through butterfly catheters. Use an alternative site if reactions develop. Abrupt discontinuation of beta-blocker therapy in patients with coronary artery disease may result in exacerbations of angina, myocardial infarction, or ventricular arrhythmias. Monitor for signs of myocardial ischemia when discontinuing RAPIBLYK. Beta-blockers may increase serum potassium. Monitor electrolytes during therapy, especially in patients with renal impairment. Beta-adrenergic blockade may mask clinical signs of hyperthyroidism. Abrupt withdrawal may precipitate thyroid storm. Patients at risk of anaphylaxis may be more reactive to allergen exposure and may be unresponsive to usual doses of epinephrine. Adverse Reactions The most common adverse reaction was hypotension in adults and pediatric patients. Drug Interactions Avoid concomitant use with negative inotropes or medications that slow heart rate or cardiac conduction. Beta-adrenergic agonists may antagonize the effects of RAPIBLYK. Use caution with catecholamine-depleting drugs due to increased risk of hypotension or bradycardia. For more information about RAPIBLYK, see Full Prescribing Information About AOP Health AOP Health is a global enterprise with roots in Austria and a mission to address unmet medical needs through innovative, science-driven therapies in cardiovascular and rare disease. Since 1996, the AOP Health Group has been recognized as a pioneer in developing integrated therapy solutions that combine deep scientific expertise with a strong commitment to patient and physician needs. Building on this foundation, AOP Health US, LLC was established in 2025 to expand the company’s impact in the United States. The team is focused on introducing its 2024 US FDA approved product for use in the critical care setting, while building the infrastructure to support healthcare professionals and the patients they serve. Rapiblyk® is a USPTO registered trademark of AOP Orphan Pharmaceuticals GmbH (Austria). © 2026 AOP Health. All rights reserved.

Drug Approval

24 Apr 2026

·www.businesswire.com

Frankfurt Higher Regional Court upholds BESREMi arbitral award in favor of AOP Health

VIENNA--(BUSINESS WIRE)--Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. The ruling confirms the award which found PharmaEssentia Corp. to be liable for certain damages. Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into an innovative treatment for rare blood cancers, particularly polycythemia vera, through a comprehensive clinical trial program. This makes BESREMi® the best investigated interferon in clinical trials in this indication as documented in the major relevant guidelines2. AOP Health had acquired the rights for both BESREMi®’s development and commercialization in the European, Commonwealth of Independent States (CIS), and Middle Eastern markets from PharmaEssentia in 2009. In its seventh year after its approval by European Medicines Agency (“EMA”), AOP Health has successfully made BESREMi® available to an estimated 12,600 patients in AOP Health’s licensed territory. First Arbitration and Set-aside Proceedings Since 2017, PharmaEssentia repeatedly attempted to terminate its agreement with AOP Health regarding BESREMi®. In October 2020, an ICC Arbitral Tribunal rejected these attempts and awarded AOP Health approx. EUR 143 million in damages and dismissed PharmaEssentia’s counterclaims in its entirety. Subsequent set-aside proceedings confirmed the arbitral award in its essentials, but found procedural flaws with respect to damage quantification, impacting the damages awarded. Second Arbitration In November 2020, PharmaEssentia initiated a legal action against AOP Health, alleging damage claims. AOP Health in turn claimed damages for delays in BESREMi®’s European approval caused by PharmaEssentia, and the misuse of AOP Health’s clinical trial data for PharmaEssentia’s US marketing authorization. The result was a partial final ICC arbitral award in favor of AOP Health, received on 17 February 2025, which found PEC guilty of intentional breaches and liable for several claims. The tribunal’s decision on the quantum of those claims is yet to be made. Ruling of Higher Regional Court of Frankfurt Confirms AOP Health’s Position In May 2025, PharmaEssentia filed an application with the Frankfurt Higher Regional Court to set aside the partial final ICC arbitral award dated 10 February 2025, arguing among other things that the award violated public order and PharmaEssentia’s right to be heard. On 24 April 2026, the Frankfurt Higher Regional Court dismissed this application in its entirety and declared the award enforceable. An appeal to the German Federal Court of Justice is possible. AOP Health believes this decision confirms its position and reinforces its commitment to patients. The company will continue to supply patients in need of ropeginterferon alfa-2b (BESREMi®), maintaining the high standards of quality patients depend on. About BESREMi® BESREMi® is the first interferon that was approved for polycythemia vera, a myeloproliferative neoplasm (MPN), indicated in the European Union as monotherapy in adults for treatment of polycythemia vera without symptomatic enlarged spleen. Its overall safety and efficacy were demonstrated in multiple clinical studies. BESREMi® (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi® is designed to be self-administered subcutaneously with a pre-filled pen. For the EMA Summary of Product Characteristics please visit: BESREMi® About AOP Health AOP Health is a global healthcare group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. At the end of 2024, AOP Health received its first U.S. FDA approval for RapiblykTM, a medication aimed at patients in intensive care units, thereby further strengthening its commitment to making therapies available for patients worldwide. The AOP Health Group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the AOP Health Group’s actions. 1 https://www.aop-health.com/global_en/press/press-releases/icc-arbitral-tribunal-ruling-aop-health/ 2 ELN Guideline (2022), NCCN Guideline (2024), Onkopedia Leitlinie (2023)

Drug ApprovalPatent Infringement

24 Apr 2026

·www.aop-health.com

Frankfurt Court Upholds Arbitral Award in favor of AOP Health

Vienna, 24.04.2026. Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: The Product Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into an innovative treatment for rare blood cancers, particularly polycythemia vera, through a comprehensive clinical trial program. This makes BESREMi® the best investigated interferon in clinical trials in this indication as documented in the major relevant guidelines2. AOP Health had acquired the rights for both BESREMi®’s development and commercialization in the European, Commonwealth of Independent States (CIS), and Middle Eastern markets from PharmaEssentia in 2009. In its seventh year after its approval by European Medicines Agency (“EMA”), AOP Health has successfully made BESREMi® available to an estimated 12,600 patients in AOP Health’s licensed territory. First Arbitration and Set-Aside Proceedings Since 2017, PharmaEssentia repeatedly attempted to terminate its agreement with AOP Health regarding BESREMi®. In October 2020, an ICC Arbitral Tribunal rejected these attempts and awarded AOP Health approx. EUR 143 million in damages and dismissed PharmaEssentia’s counterclaims in its entirety. Subsequent set-aside proceedings confirmed the arbitral award in its essentials, but found procedural flaws with respect to damage quantification, impacting the damages awarded. Second Arbitration In November 2020, PharmaEssentia initiated a legal action against AOP Health, alleging damage claims. AOP Health in turn claimed damages for delays in BESREMi®’s European approval caused by PharmaEssentia, and the misuse of AOP Health’s clinical trial data for PharmaEssentia’s US marketing authorization. The result was a partial final ICC arbitral award in favor of AOP Health, received on 17 February 2025, which found PEC guilty of intentional breaches and liable for several claims. The tribunal’s decision on the quantum of those claims is yet to be made. Ruling of Higher Regional Court of Frankfurt Confirms AOP Health’s Position In May 2025, PharmaEssentia filed an application with the Frankfurt Higher Regional Court to set aside the partial final ICC arbitral award dated 10 February 2025, arguing among other things that the award violated public order and PharmaEssentia’s right to be heard. On 24 April 2026, the Frankfurt Higher Regional Court dismissed this application in its entirety and declared the award enforceable. An appeal to the German Federal Court of Justice is possible. AOP Health believes this decision confirms its position and reinforces its commitment to patients. The company will continue to supply patients in need of ropeginterferon alfa-2b (BESREMi®), maintaining the high standards of quality patients depend on. BESREMi® is the first interferon that was approved for polycythemia vera, a myeloproliferative neoplasm (MPN), indicated in the European Union as monotherapy in adults for treatment of polycythemia vera without symptomatic enlarged spleen. Its overall safety and efficacy were demonstrated in multiple clinical studies. BESREMi® (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi® is designed to be self-administered subcutaneously with a pre-filled pen. For the EMA Summary of Product Characteristics please visit: BESREMi® AOP Health is a global healthcare group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. At the end of 2024, AOP Health received its first U.S. FDA approval for RapiblykTM, a medication aimed at patients in intensive care units, thereby further strengthening its commitment to making therapies available for patients worldwide. The AOP Health Group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim “Needs. Science. Trust.” the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the AOP Health Group’s actions. Press Contact. Mag. Nina Roth, MAS Head of Corporate Communications nina.roth[at]aop-health.com References: 1 www.aop-health.com/global_en/press/press-releases/icc-arbitral-tribunal-ruling-aop-health/2 ELN Guideline (2022), NCCN Guideline (2024), Onkopedia Leitlinie (2023) Photocredit Stock-Photo: AdobeStock_1803350112Photocredit Portrait: AOP Health/Daniel Ospelt

Drug ApprovalPatent Infringement

100 Deals associated with Landiolol Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01847	Landiolol Hydrochloride	C07AB14	DB12212

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Tachycardia, Supraventricular	Canada	Trimedica Ltd.	20 Nov 2023
Arrhythmias, Cardiac	China	Nanjing Hicin Pharmaceutical Co., Ltd.	11 Dec 2020
Atrial Fibrillation	Japan	Ono Pharmaceutical Co., Ltd.	05 Jul 2002
Atrial Flutter	Japan	Ono Pharmaceutical Co., Ltd.	05 Jul 2002
Tachycardia	Japan	Ono Pharmaceutical Co., Ltd.	05 Jul 2002
Tachycardia, Sinus	Japan	Ono Pharmaceutical Co., Ltd.	05 Jul 2002
Tachycardia, Ventricular	Japan	Ono Pharmaceutical Co., Ltd.	05 Jul 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary Artery Disease	Phase 3	Japan	Ono Pharmaceutical Co., Ltd.	01 Jun 2009
Atrial fibrillation and flutter	Phase 2	Austria	AOP Orphan Pharmaceuticals GmbH	23 Oct 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


FDA_CDER Manual	Not Applicable	Tachycardia, Supraventricular	317	Landiolol	qqctnkvrzh(etiphjdyle) = bkxzoorsqw vungokbkre (vrnzfqwezj )	Positive	22 Nov 2024
				Placebo	qqctnkvrzh(etiphjdyle) = uvtddeezur vungokbkre (vrnzfqwezj )
JPRN-jRCT2011180004 (ESMO2024) Manual	Phase 3	Non-Small Cell Lung Cancer	404	Surgery combined with continuous infusion of landiolol	ryhmxflrye(kyiiqolkvb) = wroffoxuax efdormzhbv (twqivtzvpa, 71.8 - 83.8)	Negative	14 Sep 2024
				landiolol (Surgery alone)	ryhmxflrye(kyiiqolkvb) = xmfkdremrw efdormzhbv (twqivtzvpa, 70.5 - 82.5)
EUCTR2017-002138-22-AT (Landi-SEP, Pubmed)	Phase 4	-	200	兰地洛尔	fmbnhgyfyh(opywhaxjjv) = dtylqydfyk equgvetvne (qvcpfeyxxh )	Positive	01 Sep 2024
				standard of care	fmbnhgyfyh(opywhaxjjv) = gjglgbtcfv equgvetvne (qvcpfeyxxh )
NCT00560209 (Pubmed \| Int J Cardiovasc Imaging)	Phase 2	Myocardial Ischemia	183	Landiolol hydrochloride 0.06-mg/kg	awftxowahu(lyrbipweff) = No adverse events or reactions occurred at an incidence of 5 % or greater, confirming the safety of landiolol hydrochloride zlebzwdole (jheexkpsxd )	-	01 Jun 2013
				Landiolol hydrochloride 0.125-mg/kg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis